| Burnout in the intensive care unit professionals: A systematic review CH Chuang, PC Tseng, CY Lin, KH Lin, YY Chen Medicine 95 (50), e5629, 2016 | 422 | 2016 |
| Translational research on drug development and biomarker discovery for hepatocellular carcinoma V Chew, CH Chuang, C Hsu Journal of Biomedical Science 31 (1), 22, 2024 | 6 | 2024 |
| Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus … YC Shen, TH Liu, A Nicholas, A Soyama, CT Yuan, TC Chen, S Eguchi, ... Journal of Clinical Oncology 42 (34), 4060-4070, 2024 | 3 | 2024 |
| Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma. L Wang, JC Guo, CH Chuang, G Cao, S Huang, J Liu, T Guo, TC Wu, S Li, ... Journal of Clinical Oncology 41 (16_suppl), 4058-4058, 2023 | 2 | 2023 |
| Digital versus manual pathology scoring of PD-L1 in patients with esophageal squamous cell carcinoma (ESCC). C Duan, JC Guo, J Liu, S Fu, L Wang, CH Chuang, S Huang, TC Wu, ... Journal of Clinical Oncology 42 (16_suppl), e16023-e16023, 2024 | | 2024 |
| Neoadjuvant nivolumab plus paclitaxel/cisplatin-chemo-radiotherapy (neo-NTP-CRT) followed by esophagectomy for locally advanced esophageal squamous cell carcinoma (ESCC): A … TC Huang, JC Guo, CC Lin, HY Kuo, CH Chuang, JCH Cheng, FM Hsu, ... Journal of Clinical Oncology 42 (16_suppl), e16098-e16098, 2024 | | 2024 |
| Abstract CT211: Safety of prompt initiation of durvalumab or STRIDE (single tremelimumab regular interval durvalumab) regimen as hepatocellular carcinoma (HCC) treatment for … YY Shao, CT Chen, TC Wu, TH Liu, CH Chuang, AL Cheng, CH Hsu Cancer Research 84 (7_Supplement), CT211-CT211, 2024 | | 2024 |
| MO6-2 Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC) C Chuang, TH Liu, MC Hsu, MJ Chang, AL Cheng, C Hsu Annals of Oncology 34, S1398, 2023 | | 2023 |
| Impact of pathological response and recurrence pattern on the survival of patients who develop recurrence from neoadjuvant chemoradiotherapy for locally advanced esophageal … CH Chuang, JC Guo, TC Huang, TC Wu, CH Hsu JCO Global Oncology 9 (Supplement_1), 49-49, 2023 | | 2023 |
| Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC). TC Wu, YH Liang, KH Chen, CH Chuang, YY Shao Journal of Clinical Oncology 41 (4_suppl), 36-36, 2023 | | 2023 |
| Durable Response of Immune Checkpoint Inhibitor after Failure of Gemcitabine-based Chemotherapy for a Patient with Metastatic Biliary Tract Cancer CH Chuang, C Hsu Journal of Cancer Research and Practice 8 (4), 152-158, 2021 | | 2021 |
